Acquisition Overview

Piramal Pharma Ltd (NSE: PPLPHARMA, BSE: 543635) announced the completion of an acquisition of an additional 40.67% equity stake in Yapan Bio Private Limited, a Hyderabad‑based contract development and manufacturing organization (CDMO) that specializes in process development, characterization, and Phase I and Phase II GMP manufacturing services for vaccines and biologics. The transaction was finalized on August 18 2026, with an aggregate cash consideration of ₹76 crore (approximately US$7.95 million). As a result of the deal, Piramal’s total holding in Yapan Bio increased to 74% of the company’s equity, thereby converting Yapan Bio from an associate to a wholly‑controlled subsidiary.

Strategic Rationale and Integration

The acquisition aligns with Piramal’s long‑range plan to deepen its presence in the biologics sector. Yapan Bio’s capabilities will be fully embedded within Piramal Pharma Solutions (PPS), the CDMO arm of Piramal Pharma Ltd, enhancing the group’s ability to offer integrated large‑molecule CDMO services. The subsidiary will continue to operate under the PPS structure and will support PPS’s ADCelerate™ platform – a fixed‑price, end‑to‑end solution that accelerates antibody‑drug conjugate (ADC) development from research to GMP manufacturing in as little as twelve months.

Quote from Leadership

Peter DeYoung, Chief Executive Officer of Piramal Global Pharma, stated: “This strategic investment doesn’t just fuel our long‑term growth; it also puts Patient Centricity into action. By integrating Yapan Bio’s specialized expertise into our global network, we’re empowering our partners to meet a rising global demand for complex biologics and helping patients worldwide secure continued access to the therapies they need.”

About Piramal Pharma Solutions (PPS)

PPS is a global CDMO offering end‑to‑end development and manufacturing solutions across the drug lifecycle. Its network spans facilities in North America, Europe, and Asia, providing services that include drug discovery, process and pharmaceutical development, clinical trial supplies, commercial API and finished‑dosage‑form supply, as well as specialized offerings such as highly potent APIs, antibody‑drug conjugations, sterile fill/finish, peptide products, and potent solid oral drug products. Through Yapan Bio, PPS also delivers development and manufacturing services for biologics, including vaccines and gene therapies.

About Piramal Pharma Limited

Piramal Pharma Limited (PPL) operates through three primary businesses: Piramal Pharma Solutions (the CDMO), Piramal Critical Care (a complex hospital generics business), and Piramal Consumer Healthcare (over‑the‑counter consumer and wellness products). The group maintains a global footprint with 17 development and manufacturing facilities and a distribution network covering over 100 countries. An associate company, Abbvie Therapeutics India Private Limited – a joint venture between Abbvie and Piramal – is a market leader in ophthalmology therapies in India.

Transaction Details Summary

  • Incremental stake acquired: 40.67% of Yapan Bio
  • Total post‑transaction holding: 74% (subsidiary status)
  • Cash consideration: ₹76 crore (US$7.95 million)
  • Completion date: 18 August 2026
  • Yapan Bio’s core services: process development, characterization, Phase I/II GMP manufacturing for vaccines and biologics
  • Integration: Yapan Bio will operate within PPS and bolster the ADCelerate™ platform.